Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAT1 | P18440 | 6/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 0.75 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.75 |
| ▸ | HPGD | P15428 | 1/20 | 0.75 |
| ▸ | GSK3B | P49841 | 1/20 | 0.75 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.75 |
| ▸ | MYC | P01106 | 4/20 | 0.71 |
| ▸ | MAX | P61244 | 3/20 | 0.71 |
| ▸ | CISD1 | Q9NZ45 | 3/20 | 0.71 |
| ▸ | CA2 | P00918 | 1/20 | 0.71 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.71 |
| ▸ | IL1RN | P18510 | 1/20 | 0.70 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.70 |
| ▸ | MAOA | P21397 | 1/20 | 0.67 |
| ▸ | MRE11 | P49959 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | CRHBP | P24387 | 1/20 | 0.66 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.66 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.66 |
| ▸ | CLK1 | P49759 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8174880 | 1.00 | NAT1 (1.00) | NAT1RAB9AAKR1B1HPGDGSK3B | |
| SCHEMBL8174883 | 1.00 | NAT1 (1.00) | NAT1RAB9AAKR1B1HPGDGSK3B | |
| SCHEMBL18103038 | 0.95 | NAT1 (0.91) | NAT1RAB9AAKR1B1HPGDGSK3B | |
| SCHEMBL19991146 | 0.95 | NAT1 (0.91) | NAT1RAB9AAKR1B1HPGDGSK3B | |
| SCHEMBL18102889 | 0.95 | NAT1 (0.91) | NAT1RAB9AAKR1B1HPGDGSK3B | |
| SCHEMBL18095832 | 0.91 | NAT1 (0.83) | NAT1RAB9AAKR1B1HPGDGSK3B | |
| SCHEMBL18095833 | 0.91 | NAT1 (0.83) | NAT1RAB9AAKR1B1HPGDGSK3B | |
| SCHEMBL18103024 | 0.91 | NAT1 (0.83) | NAT1RAB9AAKR1B1HPGDGSK3B | |
| SCHEMBL621989 | 0.86 | TDP1 (1.00) | NAT1RAB9AAKR1B1HPGDGSK3B | |
| SCHEMBL621990 | 0.86 | TDP1 (1.00) | NAT1RAB9AAKR1B1HPGDGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160102065-A1 | NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREOF | PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) | 2016-04-14 | — | — | US | claimed |
| US-12590127-B2 | Split photoactive yellow protein complementation system and uses thereof | PARIS SCIENCES ET LETTRES (FR) | 2026-03-31 | — | — | US | disclosed |
| WO-2024052353-A1 | PROXIMITY INDUCING SYSTEM AND USES THEREOF | SORBONNE UNIVERSITE (FR) | 2024-03-14 | — | — | WO | disclosed |
| US-20220169682-A1 | SPLIT PHOTOACTIVE YELLOW PROTEIN COMPLEMENTATION SYSTEM AND USES THEREOF | PARIS SCIENCES ET LETTRES (FR) | 2022-06-02 | — | — | US | disclosed |
| EP-3947355-A1 | SPLIT PHOTOACTIVE YELLOW PROTEIN COMPLEMENTATION SYSTEM AND USES THEREOF | Paris Sciences et Lettres (FR) | 2022-02-09 | — | — | EP | disclosed |
| US-11162951-B2 | Membrane-impermeant fluorogenic chromophores | PARIS SCIENCES ET LETTRES (FR) | 2021-11-02 | — | — | US | disclosed |
| US-11162951-B2 | Membrane-impermeant fluorogenic chromophores | PARIS SCIENCES ET LETTRES (FR) | 2021-11-02 | — | — | US | disclosed |
| WO-2020201538-A1 | SPLIT PHOTOACTIVE YELLOW PROTEIN COMPLEMENTATION SYSTEM AND USES THEREOF | PARIS SCIENCES ET LETTRES – QUARTIER LATIN (FR) | 2020-10-08 | — | — | WO | disclosed |
| EP-3404022-B1 | MEMBRANE-IMPERMEANT FLUOROGENIC CHROMOPHORES | PARIS SCIENCES LETTRES QUARTIER LATIN (FR) | 2020-10-07 | — | — | EP | disclosed |
| EP-3719007-A1 | SPLIT PHOTOACTIVE YELLOW PROTEIN COMPLEMENTATION SYSTEM AND USES THEREOF | Paris Sciences et Lettres - Quartier Latin (FR) | 2020-10-07 | — | — | EP | disclosed |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| EP-1585541-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER | NOVO NORDISK AS (DK) | 2007-11-14 | — | — | EP | disclosed |
| EP-1429763-B1 | NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER | NOVO NORDISK AS (DK) | 2007-05-30 | — | — | EP | disclosed |
| EP-0434394-B1 | Compounds for treating inflammatory bowel disease | LILLY CO ELI (US) | 1998-08-05 | — | — | EP | disclosed |
| EP-0722729-A2 | Aryl-substituted rhodanines for treating multiple sclerosis | ELI LILLY AND COMPANY (US) | 1996-07-24 | — | — | EP | disclosed |
| US-5356917-A | Antiischemic, antiinflammatory, antiarthritic agents, treat-ment of dystrophic mammals | ELI LILLY AND COMPANY (US) | 1994-10-18 | — | — | US | disclosed |
| US-5216002-A | Using benzyl substituted rhodanine derivatives as pure enantiomeric form | ELI LILLY AND COMPANY (US) | 1993-06-01 | — | — | US | disclosed |
| US-5158966-A | Aryl-substituted rhodanine derivatives | THE UNIVERSITY OF COLORADO FOUNDATION, INC. (US) | 1992-10-27 | — | — | US | disclosed |
| EP-0434394-A2 | Compounds for treating inflammatory bowel disease | ELI LILLY AND COMPANY (US) | 1991-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169682-A1 | SPLIT PHOTOACTIVE YELLOW PROTEIN COMPLEMENTATION SYSTEM AND USES THEREOF | BLVRB, IK, HBG2 | NAT1 4549/4885RAB9A 675/4885AKR1B1 3275/4885 |
| US-11162951-B2 | Membrane-impermeant fluorogenic chromophores | QRFPR, BLVRB, IK | NAT1 4674/4885RAB9A 201/4885AKR1B1 2549/4885 |
| US-20160102065-A1 | NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREOF | PPARG, PPARA, TYR | NAT1 60/4885RAB9A 3882/4885AKR1B1 1583/4885 |
| US-12590127-B2 | Split photoactive yellow protein complementation system and uses thereof | BLVRB, HBG2, Q6ZSR9 | NAT1 3594/4885RAB9A 395/4885AKR1B1 3856/4885 |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | IAPP, IRS1, HBB | NAT1 4542/4885RAB9A 1951/4885AKR1B1 3767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.